Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding
Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding
The investigators hypothesize that addition of Tranexamic acid, an antifibrinolytic agent, to
 conventional therapy will lead to an improved outcome characterized by lower transfusion
 requirements.
After informed consent is obtained patients will be randomized to receive either Tranexamic
 acid or placebo in additional to conventional therapy. All patients with gastrointestinal
 hemorrhage who are admitted to the ICU are managed in consultation with the GI physicians.
 The ICU team in consultation with the gastroenterology team will manage these patients.
 Tranexamic acid will be administered in a dose of 1 gm intravenously every 6 hours for four
 days.

 The majority of patients with GI bleeding will spontaneously stop bleeding. However, in those
 patients that do not and are hemodynamically unstable it poses a significant management
 challenge. Management of these individuals includes resuscitation followed by endoscopy as
 well as therapy guided by clinical diagnosis. With optimal therapy mortality in these
 individuals remains high and the amount of blood transfusion on occasions turns out to be
 massive and often the outcomes are futile. Tranexamic acid is an antifibrinolytic agent that
 has been shown to be associated with reduced bleeding and transfusion requirement in surgical
 patients. We would like to randomize patients to receive either Tranexamic acid or placebo in
 addition to conventional therapy and monitor outcome.

 This study should provide us with information about the efficacy of this medicine in patients
 with upper GI bleeding. Data from this trial will provide us information about utility of
 pursuing this modality of therapy.
Inclusion Criteria:

 -  All patients with GI bleed if the following criteria are met:

 -  has received 4 units of PRBCs within a 24-hour period, or

 -  has orthostatic hypotension (drop in SBP of 20mmHg or drop in DBP of 10mmHg after
 fluid resuscitation with at least 20ml/Kg of either isotonic fluid and/or PRBCs),
 or

 -  if the MAP remains below 60mmHg after fluid resuscitation, and

 -  written informed consent is obtained from the subject or legally authorized
 representative.

 Exclusion Criteria:

 -  Pregnant or lactating women

 -  Known to have gastrointestinal malignancy

 -  On anticoagulation therapy

 -  Patients with history of thromboembolism

 -  Patients with history of myocardial infarction or ischemic cerebrovascular accident

 -  Patient with end stage renal disease

 -  Patients with DNR status

 -  Incarcerated individuals